ESTRO 2024 - Abstract Book

S5169

Radiobiology - Immuno-radiobiology

ESTRO 2024

2. Yuan C, Wang Q. Comparative Analysis of the Effect of Different Radiotherapy Regimens on Lymphocyte and its Subpopulations in Breast Cancer Patients. Clin Transl Oncol (2018) 20:1219–25. doi: 10.1007/s12094-018-1851 2.

3. Lhuillier C, et al. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med (2019) 11(1):40. doi: 10.1186/s13073-019-0653-7.

4. Stanojković TP, et al. Evaluation of cytokine expression and circulating immune cell subsets as potential parameters of acute radiation toxicity in prostate cancer patients. Sci Rep (2020) 10(1):19002. doi: 10.1038/s41598 020-75812-0. 5. Singh J, et al. Investigation of circulatory cytokines in patients undergoing intensity-modulated radiotherapy (IMRT) for adenocarcinoma of the prostate and association with acute RT-induced toxicity: A prospective clinical study. Cytokine (2020) 131:155108. doi: 10.1016/j.cyto.2020.155108.

6. Wang Q, et al. Changes in T Lymphocyte Subsets in Different Tumors Before and After Radiotherapy: A Meta analysis. Front Immunol (2021) 12:648652. doi: 10.3389/fimmu.2021.648652.

7. Cytlak UM, et al. Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. Nat Rev Immunol (2022) 22(2):124-138. doi: 10.1038/s41577-021-00568-1.

8. D’Auria F, et al. Modulation of Peripheral Immune Cell Subpopulations After RapidArc/Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: Findings and Comparison With 3D Conformal/Conventional Fractionation Treatment. Front Oncol (2022) 12:829812. doi: 10.3389/fonc.2022.829812. 9. Palermo B, et al. Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients. Oncoimmunology (2023) 12(1):2174721. doi: 10.1080/2162402X.2023.2174721.

10. Antonia SJ, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med (2018) 379:2342-2350.

11. Theelen WSME, et al. Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. (2019) 5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478.

12. Formenti SC, Demaria S. Future of Radiation and Immunotherapy. Int J Radiat Oncol Biol Phys. (2020) 108(1):3 5. doi: 10.1016/j.ijrobp.2020.04.034.

13. Mondini M, et al. Radiotherapy-immunotherapy combinations-perspectives and challenges. Mol Oncol (2020) 14(7):1529-1537. doi: 10.1002/1878-0261.12658.

14. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 5:375-86. doi: 10.1038/nri1604.

1253

Digital Poster